Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

(2020) James M. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

(2020) Muthiah Vaduganathan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The first, holistic immunological model of COVID‐19: implications for prevention, diagnosis, and public health measures

(2020) Paolo Maria Matricardi et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib

(2019) Elena Maria Elli et al.   Frontiers in Oncology

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis

(2018) Lisa E. Gralinski et al.   mBio

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

(2017) Rudragouda Channappanavar et al.   Seminars in Immunopathology

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

(2013) S. Verstovsek et al.   HAEMATOLOGICA

Acute Respiratory Distress Syndrome

(2012)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recommendations for Planning Pilot Studies in Clinical and Translational Research

(2011) Charity G. Moore et al.   CTS-Clinical and Translational Science

Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis

(2011) Bianca Woehrl et al.   JOURNAL OF CLINICAL INVESTIGATION